The aim of this study is the improvement of primary diagnostics of patients with prostate cancer by detecting cancer tissue and metastasis (in lymph nodes and other organs) with Choline-PET/MRI.

Choline can be marked by a positron radiator (in this trial 18F) enabling a PET to detect the regional distribution of this substance in high local resolution. Due to the image-fusion of high resolution MRI, accumulations can be assigned exactly with anatomical structures, in order to facilitate a phase-adapted therapeutic treatment.

This study should prove, that Choline-PET/MRI is able to detect prostate cancer with a sensitivity of over 90% (9% accuracy, 95% confidence interval). PET/MRI results of 43 patients with histologically known prostate cancer (needle biopsy) will be correlated to the post-interventional histopathological results (radical prostatectomy).

• Other: 18F-Ethylcholine Positron Emission Tomography
• Other: Endorectal Magnetic Resonance Imaging (1.5T)

Inclusion Criteria:

• Histologically diagnosed prostate cancer (needle biopsy)
• Radical prostatectomy as primary treatment
• No nutrition within 12 hours before PET
• No food containing choline within 24 hous before PET
• Age > 50 years

Exclusion Criteria:

• Total endo-prothesis of the hip region
• Clinical or chemical detection of an acute infection
• Missing patient agreement
• Secondary cancer
• Surgical treatment within 3 month before PET
• Claustrophobia
• Medical drugs with choline
• Severe liver damage
• Cardiac infarction
• Bradycardia (pulse rate < 55/min)
• Allergic reaction against Neurotropan
• Bronchial asthma
• Cardiac pacemaker
• Small metal implants (e.g., clips, cochlea-implants, etc.)